Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical showcases its innovative Alzheimer’s treatment, Xanamem, at the Australian Dementia Research Forum 2024. The company’s poster detailed the drug’s dose selection process and its potential to improve cognition and slow disease progression in Alzheimer’s patients. Actinogen is currently conducting clinical trials to further validate Xanamem’s efficacy as a treatment for neurological and neuropsychiatric diseases.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.